Bristol-Myers Opdivo/Yervoy Combo Meets Main Endpoint in NSCLC Study
October 22 2019 - 8:59AM
Dow Jones News
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) Tuesday said a phase 3 study
evaluating its cancer drug Opdivo plus low-dose Yervoy combined
with chemotherapy met its primary endpoint of superior overall
survival for the first-line treatment of advanced non-small cell
lung cancer.
The New York biopharmaceutical company said the study evaluated
Opdivo plus low-dose Yervoy given concomitantly with two cycles of
chemotherapy versus chemotherapy alone.
Non-small cell lung cancer, or NSCLC, is the most common type of
lung cancer, accounting for up to 85% of diagnoses.
Bristol-Myers said it plans to complete a full evaluation of the
study results, which it said build on the benefit the combination
of Opdivo plus Yervoy has previously shown in other cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 22, 2019 08:44 ET (12:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
